Sebelius Kathleen 4
4 · Humacyte, Inc. · Filed Oct 15, 2021
Insider Transaction Report
Form 4
Humacyte, Inc.HUMA
Sebelius Kathleen
Director
Transactions
- Award
Stock Options (right to buy)
2021-10-13+8,500→ 8,500 totalExercise: $10.03Exp: 2031-10-13→ Common Stock (8,500 underlying)
Footnotes (1)
- [F1]The first 25% of the option becomes exercisable on October 13, 2022, after which 1/36 of the option will become exercisable on the 13th of each month through October 13, 2025.